Paper42469396
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Maffini E and 25 others. Bone Marrow Transplant, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Papers, record 42469396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42469396
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Transplantation Conditioning | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Humans | |
| Adult | |
| Female | |
| Male | |
| Retrospective Studies | |
| Young Adult | |
| Adolescent | |
| Remission Induction | |
| Treatment Outcome |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24065243 | Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. | Blood | 2013 | https://conductscience.org/library/papers/24065243 | PubMed |
| 2 | 23129746 | Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23129746 | PubMed |
| 3 | 27927772 | Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | Haematologica | 2017 | https://conductscience.org/library/papers/27927772 | PubMed |
| 4 | 33730842 | Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021? | Haematologica | 2021 | https://conductscience.org/library/papers/33730842 | PubMed |
| 5 | 27916512 | Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. | Biol Blood Marrow Transplant | 2017 | https://conductscience.org/library/papers/27916512 | PubMed |
| 6 | 29550381 | Conditioning intensity in HCT for AML: the jury is still out. | Lancet Haematol | 2018 | https://conductscience.org/library/papers/29550381 | PubMed |
| 7 | 36460819 | Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. | Bone Marrow Transplant | 2023 | https://conductscience.org/library/papers/36460819 | PubMed |
| 8 | 24081656 | Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. | Blood | 2013 | https://conductscience.org/library/papers/24081656 | PubMed |
| 9 | 24804873 | Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. | Cancer | 2014 | https://conductscience.org/library/papers/24804873 | PubMed |
| 10 | 39440198 | Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia. | Hemasphere | 2024 | https://conductscience.org/library/papers/39440198 | PubMed |
| 11 | 28638379 | Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. | Front Immunol | 2017 | https://conductscience.org/library/papers/28638379 | PubMed |
| 12 | 35172507 | Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. | JCO Precis Oncol | 2017 | https://conductscience.org/library/papers/35172507 | PubMed |
| 13 | 38197938 | Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. | Blood Adv | 2024 | https://conductscience.org/library/papers/38197938 | PubMed |
| 14 | 10627126 | Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. | Blood | 1999 | https://conductscience.org/library/papers/10627126 | PubMed |
| 15 | 37746158 | Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. | Hemasphere | 2023 | https://conductscience.org/library/papers/37746158 | PubMed |
| 16 | 36150050 | Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. | Blood Adv | 2022 | https://conductscience.org/library/papers/36150050 | PubMed |
| 17 | 38225386 | Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38225386 | PubMed |
| 18 | 30165887 | Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. | J Hematol Oncol | 2018 | https://conductscience.org/library/papers/30165887 | PubMed |
| 19 | 9463096 | Acute and delayed toxicities of total body irradiation. Seattle Marrow Transplant Team. | Int J Radiat Oncol Biol Phys | 1983 | https://conductscience.org/library/papers/9463096 | PubMed |
| 20 | 29550384 | Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. | Lancet Haematol | 2018 | https://conductscience.org/library/papers/29550384 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42469396
GET https://conductscience.org/api/papers/v1/42469396/authors?page=2